KCM
ACHN

Kingdon Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Kingdon Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-291,000
Closed -$2.87M – 172
2015
Q1 		$2.87M Buy
+291,000
New +$3.63M 0.12% 129
2013
Q3 		– Sell
-324,500
Closed -$2.22M – 240
2013
Q2 		$2.65M Buy
+324,500
New +$2.48M 0.16% 150

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kingdon Capital Management's ACHN Position: Q2 2015 in Review

Kingdon Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 291,000 shares — an estimated $2.87M sold.

Kingdon Capital Management first reported a position in ACHN in Q2 2013 and held it in 2 quarters. The position peaked at $2.87M in Q1 2015. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

  • Kingdon Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Kingdon Capital Management sold 291,000 Achillion Pharmaceuticals shares in Q2 2015, an estimated $2.87M.
  • Kingdon Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Kingdon Capital Management's Achillion Pharmaceuticals position peaked at $2.87M in Q1 2015.
  • 158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on Kingdon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.